Built for Reimbursement from Day One
Regulatory clearance is not commercial success. In North America’s fragmented payer landscape, where FDA approval offers no guarantee of CMS coverage, and CADTH decisions can hinge on a single provincial budget impact analysis—market access must be engineered into your product’s DNA from the earliest stages.
​
Strategic Growth AI rejects the outdated “code shopping” approach. Instead, we deploy a payer-first GTM strategy that aligns clinical development, evidence generation, and commercial execution with the exact requirements of U.S. Medicare (including Medicare Advantage), commercial insurers, CADTH, and provincial formularies. This starts during pre-clinical planning, where we embed HEOR endpoints and RWE collection into trial design, ensuring your data tells the value story payers need to hear.
​
Our integrated service delivers:
-
Coverage & Claim Pathways for all major North American payers
-
Payer-Ready Evidence Dossiers (HEOR, RWE, clinical vignettes)
-
Coding & Claim Kits optimized for clean adjudication
-
Dynamic Pricing Corridors based on budget impact and IRR/rNPV modeling
​​
Powered by SGAI Clarity Intelligence™, our platform benchmarks your evidence against real-world payer thresholds and simulates reimbursement outcomes under multiple scenarios. This eliminates guesswork and ensures your launch is not just approved, but paid for.
​
Clients achieve 10–30% faster time to paid claims, 50% shorter sales cycles, and 2.3x faster KOL activation. For biotech, medtech, and AI-health companies, this isn’t just market access, it’s your competitive moat in an era where value determines viability.